Equities Analysts Offer Predictions for TSE:EPR Q4 Earnings

Eupraxia Pharmaceuticals Inc. (TSE:EPR) – Analysts at HC Wainwright decreased their Q4 2026 earnings estimates for shares of Eupraxia Pharmaceuticals in a report issued on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.41) per share for the quarter, down from their previous estimate of ($0.40). HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ FY2027 earnings at ($1.89) EPS, FY2028 earnings at ($1.75) EPS, FY2029 earnings at ($1.36) EPS and FY2030 earnings at $0.20 EPS.

Other equities research analysts have also recently issued reports about the stock. Wedbush raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, September 24th. Royal Bank Of Canada began coverage on Eupraxia Pharmaceuticals in a report on Monday. They set a “moderate buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Strong Buy”.

Eupraxia Pharmaceuticals Price Performance

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biotechnology company developing locally acting therapies designed to improve the delivery, duration and tolerability of established medicines. The company’s platform, DiffuSphere, uses biodegradable polymeric microspheres to provide controlled and sustained drug release at targeted sites in the body. Eupraxia’s lead programs include EP-104IAR, an extended-release intra-articular formulation intended to provide longer-lasting relief for people with knee osteoarthritis, and EP-104GI, an orally administered formulation being developed for gastrointestinal diseases, including eosinophilic esophagitis.